5-Aminosalicylic Acid

5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN) .

Product Specifications

CAS Number

[89-57-6]

Product Name Alternative

Mesalamine; 5-ASA; Mesalazine

UNSPSC

12352005

Hazard Statement

H315, H317, H319, H335

Target

Endogenous Metabolite; NF-κB; PAK; PPAR

Type

Natural Products

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease; NF-κB; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/5-Aminosalicylic-acid.html

Purity

99.97

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

OC1=C(C(O)=O)C=C(N)C=C1

Molecular Formula

C7H7NO3

Molecular Weight

153.14

Precautions

H315, H317, H319, H335

References & Citations

[1]Dammann K, et al. PAK1 modulates a PPARγ/NF-κB cascade in intestinal inflammation. Biochim Biophys Acta. 2015 Oct;1853 (10 Pt A) :2349-60.|[2]Fang HM, et al. 5-aminosalicylic acid in combination with Nimesulide inhibits proliferation of colon carcinoma cells in vitro. World J Gastroenterol. 2007 May 28;13 (20) :2872-7.|[3]Rousseaux C, et al. The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ. Carcinogenesis. 2013 Nov;34 (11) :2580-6.|[4]Ramadan A, et al. Mesalazine, an osteopontin inhibitor: The potential prophylactic and remedial roles in induced liver fibrosis in rats. Chem Biol Interact. 2018 Jun 1;289:109-118.